

DAFTAR PUSTAKA

1. Bradley SH, Lawrence N, Steele C, Mohamed Z. Precocious puberty. *The BMJ* 2020;368.
2. Bräuner E V., Busch AS, Eckert-Lind C, Koch T, Hickey M, Juul A. Trends in the Incidence of Central Precocious Puberty and Normal Variant Puberty Among Children in Denmark, 1998 to 2017. *JAMA Netw Open* 2020;3(10):e2015665.
3. Batubara JR, Tridjaja B, Pulungan A. Buku Ajar Endokrinologi Anak . Edisi Kedua. Jakarta: Badan Penerbit Ikatan Dokter Anak Indonesia, 2018;
4. Schoelwer M, Eugster EA. Treatment of peripheral precocious puberty. *Endocr Dev* 2016;29:230–239.
5. Maulina F. MCCUNE-ALBRIGHT SYNDROME (MAS). 2019;
6. Dean L. McCune-Albright Syndrome. 2012;
7. Khunda S. Vaginal bleeding in children. *BJOG: An International Journal of Obstetrics and Gynaecology* Conference: RCOG World Congress 2013 Liverpool United Kingdom Conference Start: 20130624 Conference End: 20130626 Conference Publication: (var.pagings)120 ()(pp 347), 2013 Date of Publicat 2013;(var.pagings).
8. Latronico AC, Brito VN, Carel JC. Causes, diagnosis, and treatment of central precocious puberty. *Lancet Diabetes Endocrinol.* 2016;4(3):265–274.
9. Alotaibi MF. Physiology of puberty in boys and girls and pathological disorders affecting its onset. *J Adolesc.* 2019;71:63–71.
10. Abreau AP, Kaiser U. Pubertal development and regulation. *Lancet Diabetes Endocrinol* 2016;4:254–264.
11. Barstow C, Rerucha C. Evaluation of Short and Tall Stature in Children. *Am Fam Physician* 2015;92.
12. Khadilkar V, Khadilkar A, Arya A, et al. Height Velocity Percentiles in Indian Children Aged 5-17 Years. 2019;
13. Emons J, Chagin AS, Säwendahl L, Karperien M, Wit JM. Mechanisms of growth plate maturation and epiphyseal fusion. *Horm Res Paediatr.* 2011;75(6):383–391.
14. Kim YJ, Kwon A, Jung MK, et al. Incidence and Prevalence of Central Precocious Puberty in Korea: An Epidemiologic Study Based on a National Database. *Journal of Pediatrics* 2019;208:221–228.

15. Eugster EA, Rubin SD, Reiter EO, Plourde P, Jou HC, Pescovitz OH. Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: A multicenter trial. *Journal of Pediatrics* 2003;143(1):60–66.
16. Jayant SS, Walia R, Gupta R, et al. Autonomous growth hormone secretion due to McCune Albright syndrome in paediatric age group: an ominous triad. *Endocrine [homepage on the Internet]* 2023; Available from: <https://link.springer.com/10.1007/s12020-023-03333-7>
17. Spencer T, Pan KS, Collins MT, Boyce AM. The Clinical Spectrum of McCune-Albright Syndrome and Its Management. *Horm Res Paediatr.* 2020;92(6):347–356.
18. Hou JW. McCune–Albright Syndrome: Diagnosis and clinical course in eleven patients. *Pediatr Neonatol* 2018;59(4):418–420.
19. Javaid MK, Boyce A, Appelman-Dijkstra N, et al. Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: A consensus statement from the FD/MAS international consortium. *Orphanet J Rare Dis* 2019;14(1).
20. Tufano M, Ciofi D, Amendolea A, Stagi S. Auxological and Endocrinological Features in Children With McCune Albright Syndrome: A Review. *Front Endocrinol (Lausanne).* 2020;11.
21. Spencer T, Pan KS, Collins MT, Boyce AM. The Clinical Spectrum of McCune-Albright Syndrome and Its Management. *Horm Res Paediatr.* 2020;92(6):347–356.
22. Zhang AB, Zhang JY, Xue J, et al. The prevalence, diagnostic accuracy and genotype-phenotype correlation of GNAS mutations in fibrous dysplasia: a meta-analysis. *Front Genet.* 2024;15.
23. Eugster EA, Shankar R, Feezle LK, Pescovitz OH. Tamoxifen Treatment of Progressive Precocious Puberty in a Patient with McCune-Albright Syndrome. 1999;
24. Kreher NC, Eugster EA, Shankar RR. The use of tamoxifen to improve height potential in short pubertal boys. *Pediatrics* 2005;116(6):1513–1515.
25. Eugster EA, Shankar R, Feezle LK, Pescovitz OH. Tamoxifen Treatment of Progressive Precocious Puberty in a Patient with McCune-Albright Syndrome. 1999;
26. Tufano M, Ciofi D, Amendolea A, Stagi S. Auxological and Endocrinological Features in Children With McCune Albright Syndrome: A Review. *Front Endocrinol (Lausanne).* 2020;11.

27. Pedoman Pelaksanaan Stimulasi, Deteksi, dan Intervensi Dini Tumbuh Kembang Anak di Tingkat Pelayanan Kesehatan Dasar. Kementerian Kesehatan RI 2022;
28. Rosenberg SA, Zhang D, Robinson CC. Prevalence of developmental delays and participation in early intervention services for young children. *Pediatrics* 2008;121(6).
29. Glascoe FP, Byrne KE. The Accuracy of Three Developmental Screening Tests. *J Early Interv* 1993;17(4):368–379.
30. Buku Ajar Imunisasi. Pusat Pendidikan dan Pelatihan Tenaga Kesehatan, Badan PPSDM Kesehatan Kementerian Kesehatan Republik Indonesia 2020;
31. Neni Sitaresmi M, Rezeki Hadinegoro SS, Kartasasmita CB, et al. Jadwal Imunisasi Anak Umur 0-18 tahun Rekomendasi Ikatan Dokter Anak Indonesia Tahun 2020. 2020;
32. Jenderal D, Dan P, Penyakit P. Pelaksanaan BIAN dalam Rangka Melindungi Anak Indonesia dari Penyakit-penyakit yang dapat Dicegah dengan Imunisasi.
33. Cohen MA, Simmons KB, Edelman AB, Jensen JT. Tamoxifen for the prevention of unscheduled bleeding in new users of the levonorgestrel 52-mg intrauterine system: a randomized controlled trial. *Contraception* 2019;100(5):391–396.
34. Helgestam M, Andersson H, Stavreus-Evers A, Brittebo E, Olovsson M. Tamoxifen modulates cell migration and expression of angiogenesis-related genes in human endometrial endothelial cells. *American Journal of Pathology* 2012;180(6):2527–2535.
35. Fetih AN, Abbas AM, Kamel FA, Nashar IH El. Tamoxifen for treatment of abnormal uterine bleeding in etonorgestrel implant users: a randomized clinical trial. *Int J Reprod Contracept Obstet Gynecol* 2019;8(11):4462.
36. Buff Passone CG De, Kuperman H, Cabral De Menezes-Filho H, Spassapan Oliveira Esteves L, Lana Obata Giroto R, Damiani D. Tamoxifen improves final height prediction in girls with mccune-albright syndrome: A long follow-up. *Horm Res Paediatr* 2015;84(3):184–189.
37. Praktik Klinis P. IKATAN DOKTER ANAK INDONESIA 2017 Diagnosis dan Tata Laksana Pubertas Prekoks Sentral.
38. Perry MJ, Gujra S, Whitworth T, Tobias JH. Tamoxifen stimulates cancellous bone formation in long bones of female mice. *Endocrinology* 2005;146(3):1060–1065.
39. Anak L, Mccune-Albright S, Memenuhi U, Persyaratan S. KASUS PANJANG.

40. Corsello A, Spolidoro GCI, Milani GP, Agostoni C. Vitamin D in pediatric age: Current evidence, recommendations, and misunderstandings. *Front Med (Lausanne)* 2023;10.
41. Javaid MK, Boyce A, Appelman-Dijkstra N, et al. Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: A consensus statement from the FD/MAS international consortium. *Orphanet J Rare Dis* 2019;14(1).
42. Aslan SG, Tezel K, Ordu-Gökkaya NK. Fibrous dysplasia and McCune-Albright syndrome: A case report with review of literature on the rehabilitation approach. *Turk J Phys Med Rehabil* 2023;69(2):252–256.
43. Sawathiparnich P, Osuwanaratana P, Santiprabhob J, Likitmaskul S. Tamoxifen improved final height prediction in a girl with McCune-Albright Syndrome: Patient report and literature review. *Journal of Pediatric Endocrinology and Metabolism* 2006;19(1):81–86.
44. Morales L, Timmerman D, Neven P, et al. Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients. *Annals of Oncology* 2005;16(1):70–74.
45. Yang H, Luo S, Liang X, et al. The association between family impact and health-related quality of life of children with idiopathic central precocious puberty in Chongqing, China. *Health Qual Life Outcomes* 2021;19(1).
46. Moon SJ, Lee WY, Hwang JS, Hong YP, Morisky DE. Accuracy of a screening tool for medication adherence: A systematic review and meta-analysis of the Morisky Medication Adherence Scale-8. *PLoS One* 2017;12(11):1–18.
47. Eugster EA, Rubin SD, Reiter EO, Plourde P, Jou HC, Pescovitz OH. Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: A multicenter trial. *Journal of Pediatrics* 2003;143(1):60–66.